Skip to main content
Fig. 7 | BMC Cancer

Fig. 7

From: Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors

Fig. 7

IGF-1Rki and PARP inhibitor combination effect in HR Proficient cancer cells. SKOV3 (a) and BT-20 (b) cancer cells were treated with increasing doses of IGF-1Rki in the presence of sublethal doses of 1uM (a) or 0.5uM (b) olaparib for 7 days and survival was determined using the clonogenic assay. c The combination index was calculated where CI < 1 indicates synergy between the two drugs. Data represents the average of four independent experiments. *p value <0.05

Back to article page